Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c] isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity

被引:38
作者
Antony, Smitha
Agama, Keli K.
Miao, Ze-Hong
Hollingshead, Melinda
Holbeck, Susan L.
Wright, Mollie H.
Varticovski, Lyuba
Nagarajan, Muthukaman
Morrell, Andrew
Cushman, Mark
Pommier, Yves
机构
[1] NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Biol Testing Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Dev Therapeut Program, Informat Technol Branch, NIH, Bethesda, MD 20892 USA
[4] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
关键词
D O I
10.1124/mol.106.024372
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Indenoisoquinolines are topoisomerase (Top) I inhibitors developed to overcome some of the limitations of camptothecins and expand their anticancer spectrum. Bis-1,3-{(5,6-dihydro5,11-diketo-11H-indeno[1,2-c] isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357) is a novel dimeric indenoisoquinoline derivative with potent antiproliferative activity in the NCI-60 cell line panel, promising hollow fiber activity (score of 32) and activity against xenografts. Submicromolar concentrations of the bisindenoisoquinoline NSC 727357 induce Top1 cleavage complexes at specific sites in biochemical assays. At higher concentrations, inhibition of Top1 catalytic activity and DNA intercalation is observed. NSC 727357 also induces a limited number of Top2-DNA cleavage complexes. In contrast to the effect of other Top1 inhibitors, cells treated with the bisindenoisoquinoline NSC 727357 show an arrest of cell cycle progression in G 1 with no significant inhibition of DNA synthesis after a short exposure to the drug. Moreover, unlike camptothecin and the indenoisoquinoline MJ-III-65 (NSC 706744, 6-[3-(2-hydroxyethyl) aminopropyl]-5,6-dihydro-5,11-diketo-2,3-dimethoxy-(methylenedioxy)-11H-indeno[1,2c] isoquinoline hydrochloride), the cytotoxicity of bisindenoisoquinoline NSC 727357 is only partially dependent on Top1 and p53, indicating that this drug has additional targets besides Top1 and Top2.
引用
收藏
页码:1109 / 1120
页数:12
相关论文
共 51 条
[1]   Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex [J].
Adams, DJ ;
da Silva, MW ;
Flowers, JL ;
Kohlhagen, G ;
Pommier, Y ;
Colvin, OM ;
Manikumar, G ;
Wani, MC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :135-144
[2]   Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison [J].
Antony, S ;
Kohlhagen, G ;
Agama, K ;
Jayaraman, M ;
Cao, SS ;
Durrani, FA ;
Rustum, YM ;
Cushman, M ;
Pommier, Y .
MOLECULAR PHARMACOLOGY, 2005, 67 (02) :523-530
[3]  
Antony S, 2003, CANCER RES, V63, P7428
[4]  
BJORNSTI MA, 1989, CANCER RES, V49, P6318
[5]  
Bozko P, 2002, ACTA BIOCHIM POL, V49, P109
[6]   New analogues of amonafide and elinafide, containing aromatic heterocycles:: Synthesis, antitumor activity, molecular modeling, and DNA binding properties [J].
Braña, MF ;
Cacho, M ;
García, MA ;
de Pascual-Teresa, B ;
Ramos, A ;
Domínguez, MT ;
Pozuelo, JM ;
Abradelo, C ;
Rey-Stolle, MF ;
Yuste, M ;
Bánez-Coronel, M ;
Lacal, JC .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1391-1399
[7]   DNA ligation catalyzed by human topoisomerase IIα [J].
Bromberg, KD ;
Vélez-Cruz, R ;
Burgin, AB ;
Osheroff, N .
BIOCHEMISTRY, 2004, 43 (42) :13416-13423
[8]   DIACRIDINES - DOUBLE INTERCALATORS AS CHEMOTHERAPEUTIC-AGENTS [J].
CANELLAKIS, ES ;
FICO, RM ;
SARRIS, AH ;
SHAW, YH .
BIOCHEMICAL PHARMACOLOGY, 1976, 25 (02) :231-236
[9]  
Capranico Giovanni, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P335, DOI 10.2174/1568011043352885
[10]   Synthesis of new indeno[1,2-c]isoquinolines:: Cytotoxic non-camptothecin topoisomerase I inhibitors [J].
Cushman, M ;
Jayaraman, M ;
Vroman, JA ;
Fukunaga, AK ;
Fox, BM ;
Kohlhagen, G ;
Strumberg, D ;
Pommier, Y .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3688-3698